AKT1 and breast cancer: In metastatic breast cancer cells, blocking PI3K/AKT activity reverses TβRII expression to a very low level (Fig. 7f,g; Supplementary Fig. 7d), demonstrating that TβRII-mediated oncogenic TGF-β signalling is supported by AKT activity.